Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
Status:
Completed
Trial end date:
2020-07-08
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the efficacy and safety of risankizumab
compared with secukinumab for the treatment of adult subjects with moderate to severe plaque
psoriasis who are candidates for systemic therapy.